Nutriband Inc. (NTRB)Healthcare | Biotechnology | Orlando, United States | NasdaqCM
4.30 USD
+0.20
(4.878%)
⇧
(April 17, 2026, 2:56 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:16 p.m. EDT
NTRB shows a volatile price history with recent dips and spikes, indicating potential short-term momentum opportunities. However, the negative earnings and poor long-term performance suggest caution for long-term investors. The lack of dividend history and weak fundamentals further discourage investment in this stock. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.111829 |
| AutoETS | 0.115877 |
| AutoARIMA | 0.115881 |
| AutoTheta | 0.139737 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 10.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.571 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.418 |
| Revenue per Share | 0.2 |
| Market Cap | 52,352,004 |
| Forward P/E | -18.70 |
| Beta | 1.93 |
| Website | https://www.nutriband.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.20117188 |
| Address1 | 121 South Orange Avenue |
| Address2 | Suite 1500 |
| All Time High | 11.78 |
| All Time Low | 1.53 |
| Ask | 5.12 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 7,210 |
| Average Daily Volume3 Month | 12,680 |
| Average Volume | 12,680 |
| Average Volume10Days | 7,210 |
| Beta | 1.929 |
| Bid | 3.03 |
| Bid Size | 2 |
| Book Value | 0.621 |
| City | Orlando |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.3 |
| Current Ratio | 7.527 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.3 |
| Day Low | 3.99 |
| Debt To Equity | 3.418 |
| Display Name | Nutriband |
| Dividend Date | 1,563,926,400 |
| Earnings Timestamp End | 1,757,102,400 |
| Earnings Timestamp Start | 1,756,756,800 |
| Ebitda | -9,029,840 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.947 |
| Enterprise To Revenue | 19.605 |
| Enterprise Value | 44,666,828 |
| Eps Forward | -0.23 |
| Eps Trailing Twelve Months | -3.05 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.044 |
| Fifty Day Average Change | 0.25600004 |
| Fifty Day Average Change Percent | 0.063303664 |
| Fifty Two Week Change Percent | -20.117188 |
| Fifty Two Week High | 11.678 |
| Fifty Two Week High Change | -7.3780003 |
| Fifty Two Week High Change Percent | -0.6317863 |
| Fifty Two Week Low | 3.42 |
| Fifty Two Week Low Change | 0.8800001 |
| Fifty Two Week Low Change Percent | 0.25730997 |
| Fifty Two Week Range | 3.42 - 11.678 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,095,000,000 |
| Float Shares | 4,908,586 |
| Forward Eps | -0.23 |
| Forward P E | -18.695652 |
| Free Cashflow | -2,588,350 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.33503 |
| Gross Profits | 763,311 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.74379 |
| Held Percent Institutions | 0.0286 |
| Implied Shares Outstanding | 12,174,884 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,738,281,600 |
| Last Split Date | 1,660,262,400 |
| Last Split Factor | 1,166:1000 |
| Long Business Summary | Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida. |
| Long Name | Nutriband Inc. |
| Market | us_market |
| Market Cap | 52,352,004 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_345353860 |
| Most Recent Quarter | 1,761,868,800 |
| Net Income To Common | -34,592,176 |
| Next Fiscal Year End | 1,769,817,600 |
| Non Diluted Market Cap | 49,795,271 |
| Number Of Analyst Opinions | 1 |
| Open | 4.06 |
| Operating Cashflow | -5,642,044 |
| Operating Margins | -11.21296 |
| Payout Ratio | 0.0 |
| Phone | 407 377 6695 |
| Previous Close | 4.1 |
| Price Hint | 4 |
| Price To Book | 6.924316 |
| Price To Sales Trailing12 Months | 22.978327 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.067 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.20000029 |
| Regular Market Change Percent | 4.878056 |
| Regular Market Day High | 4.3 |
| Regular Market Day Low | 3.99 |
| Regular Market Day Range | 3.99 - 4.3 |
| Regular Market Open | 4.06 |
| Regular Market Previous Close | 4.1 |
| Regular Market Price | 4.3 |
| Regular Market Time | 1,776,452,209 |
| Regular Market Volume | 15,143 |
| Return On Assets | -0.55222 |
| Return On Equity | -1.3607601 |
| Revenue Growth | -0.464 |
| Revenue Per Share | 0.2 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,174,883 |
| Shares Percent Shares Out | 0.0179 |
| Shares Short | 217,557 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 203,148 |
| Short Name | Nutriband Inc. |
| Short Percent Of Float | 0.0442 |
| Short Ratio | 14.85 |
| Source Interval | 15 |
| State | FL |
| Symbol | NTRB |
| Target High Price | 15.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 15.0 |
| Target Median Price | 15.0 |
| Total Cash | 5,312,177 |
| Total Cash Per Share | 0.437 |
| Total Debt | 258,025 |
| Total Revenue | 2,278,321 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.7269 |
| Two Hundred Day Average Change | -1.4268999 |
| Two Hundred Day Average Change Percent | -0.24915746 |
| Type Disp | Equity |
| Volume | 15,143 |
| Website | https://www.nutriband.com |
| Zip | 32,801 |